In the last 12 months, insiders at Greenwich LifeSciences, Inc. ($GLSI) filed 76 transactions with the SEC: 68 open-market purchases totaling $5,074,337 and 0 sales totaling $0. Net insider sentiment: net buying.
Greenwich LifeSciences, Inc. operates in the Pharmaceutical preparations industry (Life sciences sector).
Most Active Insiders
- Patel Snehal (CEO and CFO) — 57 transactions totaling $4,971,477
- Thompson Jaye (VP Clinical Reg Affairs) — 15 transactions totaling $102,860
- Hallock Kenneth (Director) — 1 transaction totaling $0
- McWilliams David (Director) — 1 transaction totaling $0
- Daugherty Frank Joseph (Chief Medical Officer) — 1 transaction totaling $0
View all SEC Filings for Greenwich LifeSciences, Inc. (GLSI).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 13, 2026 | Patel Snehal | CEO and CFO | P | Common Stock | 1800 | $29.83 | 5,604,102.0000 | 13,854,539 | 0.03% | 0.01% |
| Jan. 12, 2026 | Patel Snehal | CEO and CFO | P | Common Stock | 2900 | $27.54 | 5,602,302.0000 | 13,854,539 | 0.05% | 0.02% |
| Dec. 31, 2025 | Patel Snehal | CEO and CFO | P | Common Stock | 4300 | $21.36 | 5,599,402.0000 | 13,854,539 | 0.08% | 0.03% |
| Dec. 30, 2025 | Patel Snehal | CEO and CFO | P | Common Stock | 2900 | $21.73 | 5,595,102.0000 | 13,854,539 | 0.05% | 0.02% |
| Dec. 18, 2025 | Patel Snehal | CEO and CFO | P | Common Stock | 4100 | $12.62 | 5,592,202.0000 | 13,854,539 | 0.07% | 0.03% |
| Nov. 25, 2025 | Patel Snehal | CEO and CFO | P | Common Stock | 4600 | $8.37 | 5,588,102.0000 | 13,854,539 | 0.08% | 0.03% |
| Nov. 13, 2025 | Patel Snehal | CEO and CFO | A | Stock Options | 100000 | $0.00 | 2,347,462.0000 | 13,854,539 | 4.45% | 0.72% |
| Nov. 7, 2025 | Patel Snehal | CEO and CFO | P | Common Stock | 10600 | $8.43 | 5,583,502.0000 | 13,854,539 | 0.19% | 0.08% |
| Oct. 31, 2025 | Patel Snehal | CEO and CFO | P | Common Stock | 2300 | $9.26 | 5,572,902.0000 | 13,854,539 | 0.04% | 0.02% |
| April 25, 2025 | Patel Snehal | CEO and CFO | P | Common Stock | 3600 | $9.88 | 5,570,602.0000 | 13,273,539 | 0.06% | 0.03% |
| April 17, 2025 | Patel Snehal | CEO and CFO | P | Common Stock | 5400 | $8.98 | 5,567,002.0000 | 13,273,539 | 0.10% | 0.04% |
| April 7, 2025 | Patel Snehal | CEO and CFO | P | Common Stock | 3600 | $9.10 | 5,561,602.0000 | 0 | 0.06% | 0.00% |
| April 4, 2025 | Patel Snehal | CEO and CFO | P | Common Stock | 5500 | $8.73 | 5,558,002.0000 | 0 | 0.10% | 0.00% |
| Jan. 10, 2025 | Patel Snehal | CEO and CFO | P | Common Stock | 2500 | $12.51 | 5,552,502.0000 | 0 | 0.05% | 0.00% |
| Jan. 6, 2025 | Patel Snehal | CEO and CFO | P | Common Stock | 1100 | $13.31 | 5,548,202.0000 | 0 | 0.02% | 0.00% |
| Jan. 7, 2025 | Patel Snehal | CEO and CFO | P | Common Stock | 1800 | $13.75 | 5,550,002.0000 | 0 | 0.03% | 0.00% |
| Jan. 3, 2025 | Patel Snehal | CEO and CFO | P | Common Stock | 3400 | $12.95 | 5,547,102.0000 | 0 | 0.06% | 0.00% |
| Jan. 2, 2025 | Patel Snehal | CEO and CFO | P | Common Stock | 2000 | $11.97 | 5,543,702.0000 | 0 | 0.04% | 0.00% |
| Dec. 31, 2024 | Patel Snehal | CEO and CFO | P | Common Stock | 2400 | $11.36 | 5,541,702.0000 | 0 | 0.04% | 0.00% |
| Dec. 30, 2024 | Patel Snehal | CEO and CFO | P | Common Stock | 3200 | $11.12 | 5,539,302.0000 | 0 | 0.06% | 0.00% |
| Dec. 24, 2024 | McWilliams David | Director | A | Stock Options | 61984 | $0.00 | 123,968.0000 | 0 | 100.00% | 0.00% |
| Dec. 24, 2024 | Thompson Jaye | VP Clinical Reg Affairs | A | Stock Options | 149818 | $0.00 | 299,636.0000 | 0 | 100.00% | 0.00% |
| Dec. 24, 2024 | Rothe Eric | Director | A | Stock Options | 41349 | $0.00 | 82,698.0000 | 0 | 100.00% | 0.00% |
| Dec. 24, 2024 | Patel Snehal | CEO and CFO | A | Stock Options | 25008 | $0.00 | 4,469,916.0000 | 0 | 0.56% | 0.00% |
| Dec. 24, 2024 | Patel Snehal | CEO and CFO | A | Stock Options | 1148723 | $0.00 | 4,469,916.0000 | 0 | 34.59% | 0.00% |
| Dec. 24, 2024 | Daugherty Frank Joseph | Chief Medical Officer | A | Stock Options | 104890 | $0.00 | 209,780.0000 | 0 | 100.00% | 0.00% |
| Dec. 24, 2024 | Hallock Kenneth | Director | A | Stock Options | 41349 | $0.00 | 82,698.0000 | 0 | 100.00% | 0.00% |
| Nov. 21, 2024 | Thompson Jaye | VP Clinical Reg Affairs | P | Common Stock | 1000 | $12.91 | 264,148.0000 | 0 | 0.38% | 0.00% |
| Sept. 26, 2024 | Patel Snehal | CEO and CFO | P | Common Stock | 1500 | $14.63 | 5,536,102.0000 | 0 | 0.03% | 0.00% |
| Aug. 12, 2024 | Thompson Jaye | VP Clinical Reg Affairs | P | Common Stock | 800 | $13.85 | 263,148.0000 | 0 | 0.30% | 0.00% |
| Aug. 6, 2024 | Patel Snehal | CEO and CFO | P | Common Stock | 2000 | $13.81 | 5,534,602.0000 | 0 | 0.04% | 0.00% |
| Aug. 5, 2024 | Patel Snehal | CEO and CFO | P | Common Stock | 5500 | $13.18 | 5,532,602.0000 | 0 | 0.10% | 0.00% |
| Aug. 2, 2024 | Thompson Jaye | VP Clinical Reg Affairs | P | Common Stock | 1000 | $15.15 | 262,348.0000 | 0 | 0.38% | 0.00% |
| July 23, 2024 | Patel Snehal | CEO and CFO | P | Common Stock | 1500 | $15.89 | 5,527,102.0000 | 0 | 0.03% | 0.00% |
| July 18, 2024 | Thompson Jaye | VP Clinical Reg Affairs | P | Common Stock | 1000 | $16.00 | 261,348.0000 | 0 | 0.38% | 0.00% |
| June 13, 2024 | Patel Snehal | CEO and CFO | P | Common Stock | 174825 | $14.30 | 5,525,602.0000 | 0 | 3.27% | 0.00% |
| April 1, 2024 | Patel Snehal | CEO and CFO | P | Common Stock | 3000 | $19.08 | 5,350,777.0000 | 0 | 0.06% | 0.00% |
| March 22, 2024 | Patel Snehal | CEO and CFO | P | Common Stock | 2500 | $19.98 | 5,347,777.0000 | 0 | 0.05% | 0.00% |
| March 20, 2024 | Patel Snehal | CEO and CFO | P | Common Stock | 1500 | $17.68 | 5,345,277.0000 | 0 | 0.03% | 0.00% |
| March 5, 2024 | Patel Snehal | CEO and CFO | P | Common Stock | 30500 | $12.49 | 5,343,777.0000 | 0 | 0.57% | 0.00% |
| March 5, 2024 | Patel Snehal | CEO and CFO | P | Common Stock | 3500 | $12.49 | 5,343,777.0000 | 0 | 0.07% | 0.00% |
| March 4, 2024 | Patel Snehal | CEO and CFO | P | Common Stock | 4100 | $13.03 | 5,340,277.0000 | 0 | 0.08% | 0.00% |
| Feb. 16, 2024 | Patel Snehal | CEO and CFO | P | Common Stock | 10800 | $11.16 | 5,336,177.0000 | 0 | 0.20% | 0.00% |
| Feb. 15, 2024 | Patel Snehal | CEO and CFO | P | Common Stock | 12700 | $11.07 | 5,325,377.0000 | 0 | 0.24% | 0.00% |
| Nov. 10, 2023 | Patel Snehal | CEO and CFO | P | Common Stock | 5000 | $10.17 | 5,312,677.0000 | 0 | 0.09% | 0.00% |
| Nov. 3, 2023 | Patel Snehal | CEO and CFO | P | Common Stock | 3500 | $9.11 | 5,307,677.0000 | 0 | 0.07% | 0.00% |
| Oct. 27, 2023 | Thompson Jaye | VP Clinical Reg Affairs | P | Common Stock | 500 | $8.57 | 260,348.0000 | 0 | 0.19% | 0.00% |
| Oct. 26, 2023 | Patel Snehal | CEO and CFO | P | Common Stock | 2500 | $7.97 | 5,304,177.0000 | 0 | 0.05% | 0.00% |
| Oct. 25, 2023 | Patel Snehal | CEO and CFO | P | Common Stock | 2500 | $7.91 | 5,301,677.0000 | 0 | 0.05% | 0.00% |
| Oct. 10, 2023 | Patel Snehal | CEO and CFO | P | Common Stock | 1000 | $9.07 | 5,299,177.0000 | 0 | 0.02% | 0.00% |
| Oct. 4, 2023 | Patel Snehal | CEO and CFO | P | Common Stock | 2000 | $8.63 | 5,298,177.0000 | 0 | 0.04% | 0.00% |
| Sept. 26, 2023 | Thompson Jaye | VP Clinical Reg Affairs | P | Common Stock | 600 | $8.71 | 259,848.0000 | 0 | 0.23% | 0.00% |
| Sept. 19, 2023 | Patel Snehal | CEO and CFO | P | Common Stock | 4000 | $8.95 | 5,296,177.0000 | 0 | 0.08% | 0.00% |
| Sept. 11, 2023 | Patel Snehal | CEO and CFO | P | Common Stock | 1000 | $9.48 | 5,292,177.0000 | 0 | 0.02% | 0.00% |
| Aug. 22, 2023 | Patel Snehal | CEO and CFO | P | Common Stock | 1000 | $9.97 | 5,291,177.0000 | 0 | 0.02% | 0.00% |
| Aug. 4, 2023 | Patel Snehal | CEO and CFO | P | Common Stock | 2000 | $10.55 | 5,290,177.0000 | 0 | 0.04% | 0.00% |
| July 21, 2023 | Patel Snehal | CEO and CFO | P | Common Stock | 1000 | $9.20 | 5,288,177.0000 | 0 | 0.02% | 0.00% |
| July 13, 2023 | Thompson Jaye | VP Clinical Reg Affairs | P | Common Stock | 250 | $9.49 | 259,248.0000 | 0 | 0.10% | 0.00% |
| May 17, 2023 | Patel Snehal | CEO and CFO | P | Common Stock | 1000 | $11.69 | 5,287,177.0000 | 0 | 0.02% | 0.00% |
| April 28, 2023 | Thompson Jaye | VP Clinical Reg Affairs | P | Common Stock | 250 | $11.22 | 258,998.0000 | 0 | 0.10% | 0.00% |
| April 19, 2023 | Patel Snehal | CEO and CFO | P | Common Stock | 7000 | $11.10 | 5,286,177.0000 | 0 | 0.13% | 0.00% |
| April 18, 2023 | Patel Snehal | CEO and CFO | P | Common Stock | 2000 | $11.12 | 5,279,177.0000 | 0 | 0.04% | 0.00% |
| April 11, 2023 | Thompson Jaye | VP Clinical Reg Affairs | P | Common Stock | 1000 | $11.87 | 258,745.0000 | 0 | 0.39% | 0.00% |
| April 11, 2023 | Patel Snehal | CEO and CFO | P | Common Stock | 5000 | $12.42 | 5,271,177.0000 | 0 | 0.09% | 0.00% |
| March 15, 2023 | Thompson Jaye | VP Clinical Reg Affairs | P | Common Stock | 250 | $12.71 | 257,745.0000 | 0 | 0.10% | 0.00% |
| March 10, 2023 | Patel Snehal | CEO and CFO | P | Common Stock | 1000 | $12.12 | 2,737,486.0000 | 0 | 0.04% | 0.00% |
| Feb. 24, 2023 | Thompson Jaye | VP Clinical Reg Affairs | P | Common Stock | 250 | $15.40 | 257,495.0000 | 0 | 0.10% | 0.00% |
| Feb. 17, 2023 | Patel Snehal | CEO and CFO | P | Common Stock | 600 | $16.53 | 2,736,486.0000 | 0 | 0.02% | 0.00% |
| Feb. 10, 2023 | Patel Snehal | CEO and CFO | P | Common Stock | 1000 | $18.68 | 2,735,886.0000 | 0 | 0.04% | 0.00% |
| Feb. 3, 2023 | Thompson Jaye | VP Clinical Reg Affairs | P | Common Stock | 250 | $20.84 | 257,245.0000 | 0 | 0.10% | 0.00% |
| Jan. 27, 2023 | Patel Snehal | CEO and CFO | P | Common Stock | 2000 | $19.35 | 2,734,886.0000 | 0 | 0.07% | 0.00% |
| Jan. 27, 2023 | Thompson Jaye | VP Clinical Reg Affairs | P | Common Stock | 250 | $19.20 | 256,995.0000 | 0 | 0.10% | 0.00% |
| Jan. 20, 2023 | Patel Snehal | CEO and CFO | P | Common Stock | 1500 | $17.37 | 2,732,886.0000 | 0 | 0.05% | 0.00% |
| Jan. 13, 2023 | Thompson Jaye | VP Clinical Reg Affairs | P | Common Stock | 250 | $16.50 | 256,745.0000 | 0 | 0.10% | 0.00% |
| Jan. 6, 2023 | Patel Snehal | CEO and CFO | P | Common Stock | 1500 | $15.18 | 2,731,386.0000 | 0 | 0.05% | 0.00% |
| Dec. 29, 2022 | Patel Snehal | CEO and CFO | P | Common Stock | 4000 | $15.19 | 2,729,886.0000 | 0 | 0.15% | 0.00% |